

In the Description

The paragraph on page 3, lines 8 to 14, has been amended as follows:

B1
The taxoids can be, for example, docetaxel or paclitaxel. Examples of the type of cancers that can be treated include breast, ovarian, lung, head and neck, gastric, pancreatic, melanomas and soft tissue sarcomas. An example of a preferred embodiment of the present invention involves the treatment of non-small cell lung cancer.

In the Claims

Please add the following claim.

B2
30. (New) The method of claim 1 wherein said cancer is lung cancer.

REMARKS

The above amendment to the description is editorial in nature. Basis for added Claim 30 appears in the present application on page 3, lines 9 to 11.


Attached hereto is a marked-up version of the changes made to the description by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Applicant Bruno
Application No. 09/869,685

Page 3
December 30, 2002

Enclosed is a check for \$18.00 to cover the cost of newly presented Claim 30. The Commissioner is hereby authorized to charge any necessary fees or credit any overpayment associated with this communication to Deposit Account No. 19-5425.

Respectfully submitted,



Jonathan M. Dermott, Ph.D.
Registration No. 48,608

SYNNESTVEDT & LECHNER LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
(215) 923-4466 - telephone
(215) 923-2189 - facsimile

M:\JDermott\Aventis Pharma\23,565-A USA\2nd preliminary amendment2.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Description

The paragraph on page 3, lines 8 to 14, has been amended as follows:

The taxoids can be, for example, docetaxel or paclitaxel. Examples of the type of cancers that can be treated include breast, ovarian, lung, head and neck, gastric, pancreatic, melanomas and soft tissue sarcomas. An example of a preferred[of a preferred] embodiment of the present invention involves the treatment of non-small cell lung cancer.